CAS No. 1887095-82-0
Chemical Structure
Check the
RapaLink-1
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
| IUPAC Name | N-[4-[4-amino-3-(2-amino-1,3-benzoxazol-5-yl)pyrazolo[3,4-d]pyrimidin-1-yl]butyl]-3-[2-[2-[2-[2-[2-[2-[2-[2-[4-[2-[(1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl]oxyethoxymethyl]triazol-1-yl]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanamide | |
|---|---|---|
| CAS Number | 1887095-82-0 | |
| Molecular Formula |
C91H138N12O24 |
|
| Molecular Weight (MW) | 1784.14 | |
| InChIKey | QDOGZMBPRITPMZ-SLBWSSLNSA-N |
RapaLink-1 is a third-generation bivalent inhibitor of mechanistic target of rapamycin (mTOR) that simultaneously engages the FKBP12-binding domain and the kinase ATP-binding site. By potently blocking both mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) pathways, it suppresses downstream phosphorylation of S6 kinase and AKT. This inhibition overcomes resistance mediated by mTOR mutations, resulting in durable suppression of cancer cell proliferation and tumor growth. [1]
|
Concentration
Volume
Mass
|
|---|
Note: Technical data last updated: Sep 1, 2026.